Specification
| Target | IFNAR1 |
| Clone | Anifrolumab |
| Isotype | Human IgG1(K214R/L351F/L352E/P448S)-Kappa |
| Expression System | CHO |
| Purification | Protein A |
| Recommended Isotope Control | |
| Recommended Dilution Buffer | PBS, pH 7.101 |
| Formulation | PBS, pH 5.0,Contains no stabilizers or preservatives |
| Endotoxin | <1EU/mg Determined by LAL gel clotting assay |
| Purity | >95% Determined by SDS-PAGE |
| Sterility | 0.2 μM filtered |
| Storage | This antibody can be storaged at 2°C to 8 °C for 2 weeks under sterile conditions;-20°C for 3 months under sterile conditions;-70°C for 36 months under sterile conditions.Avoid repeated freeze-thaw. |
| Disclaim | For Research Use Only |
Background
| Background | Anifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus.7,11 The standard therapy for systemic lupus erythematosus consists of antimalarials like hydroxychloroquine, glucocorticoids like dexamethasone, and disease modifying antirheumatic drugs like methotrexate. Three monoclonal antibodies (anifrolumab, rontalizumab, and sifalimumab) that target the type 1 interferon pathway entered clinical trials as potential treatments for systemic lupus erythematosus, but so far only anifrolumab has been approved. |
QC Data
| Note | Please contact us for QC Data |
| Product Image (Reference Only) |  |